Welcome to our dedicated page for Biophytis Sa news (Ticker: BPTSY), a resource for investors and traders seeking the latest updates and insights on Biophytis Sa stock.
Biophytis SA (BPTSY) is a clinical-stage biotechnology company pioneering therapies for age-related diseases, with its lead candidate BIO101 targeting conditions from sarcopenia to respiratory disorders. This news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access real-time announcements about phase advancements in key programs like the Phase 3-ready sarcopenia trial, licensing agreements with global pharmaceutical groups, and collaborative research initiatives. Our curated collection ensures you stay informed about material events affecting BPTSY's position in the biopharma sector.
Content spans trial result disclosures, FDA/EMA regulatory communications, intellectual property updates, and partnership announcements with entities like AskHelpU. Bookmark this page for streamlined tracking of BPTSY's progress in developing therapies for aging populations worldwide.
Biophytis SA is strengthening its position in developing treatments for preserving muscle function in patients with obesity treated with GLP-1 therapies. The company's drug candidate BIO101, when combined with GLP-1 medications, has shown promising preclinical results in enabling high-quality weight loss while improving muscle function and strength.
While GLP-1 treatments are effective for weight loss, they can cause concerning muscle mass loss. Biophytis aims to address this issue by focusing on quality weight loss - reducing fat while preserving muscle mass and improving mobility. The company is targeting a specific market segment of obesity patients using GLP-1 therapies, with the global obesity market projected to reach $100 billion by 2030.
This development addresses a significant unmet need, as 96% of obesity patients experience muscle strength impairment. Biophytis positions itself as the only market player primarily focused on muscle quality and mobility restoration in combination with GLP-1 treatments.
Biophytis has confirmed the launch of its Phase 2 OBA clinical trial for obesity treatment, set to commence in 2025. The study will evaluate BIO101's efficacy and safety in reducing muscle strength loss caused by GLP-1 agonists in obesity patients.
Following a recent €2.6 million capital increase and promising preclinical results presented at the 15th International Conference on Frailty and Sarcopenia, the company is advancing BIO101's clinical development. The program received FDA IND clearance in July 2024, with expertise from obesity specialist Professor Marc-André Cornier.
The company's current priority is securing a pharmaceutical partner to co-develop BIO101 in obesity, supporting clinical and regulatory development through marketing authorization and product launch in North America.
Biophytis has revealed new preclinical data for its investigational drug BIO101 at the 15th International Conference on Frailty and Sarcopenia Research. The study shows that BIO101, when combined with GLP-1, significantly improved mobility and grip strength in diet-induced obese mice over a four-week treatment period.
The research demonstrates that the drug combination compensates for muscle contractility alterations caused by GLP-1 in isolated muscle tests. Previous early-phase clinical trials, including the SARA-INT (Phase 2) study on sarcopenic obesity and Quinolia (Phase 1-2) study, showed improved muscle strength and mobility in BIO101-treated obese patients compared to placebo groups.
This development addresses a significant health concern, as 96% of obesity patients report muscle strength decline. With obesity affecting nearly one billion people globally, Biophytis aims to advance BIO101's development in combination with GLP-1 through their Phase 2 OBA clinical trial.
Biophytis (FP: ALBPS) has announced the publication of its Phase 2 clinical trial SARA-INT results for BIO101 in the Journal of Cachexia, Sarcopenia and Muscle. The trial demonstrated promising efficacy for treating sarcopenia, showing clinically meaningful improvement in the 400-meter walk test at 350mg bid dosing.
Key findings include:
- Excellent safety profile with no serious adverse events
- Significant treatment effects versus placebo in slow walkers and sarcopenic obesity subpopulations
- Progress in obtaining Phase 3 trial regulatory approvals
The company is advancing discussions with a major pharmaceutical company in China and other Asian partners. Notably, sarcopenia affects 121-194 million people globally, with no current therapeutic solutions available. Biophytis positions itself as the most advanced company developing treatment for this age-related condition.
Biophytis SA (FP: ALBPS) has announced its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), scheduled for March 12-14 in Toulouse. This prestigious annual scientific event focuses on advancing clinical trials for frail older adults and brings together researchers, clinicians, and industry professionals.
During a special session on obesity-associated sarcopenia, Biophytis will present the rationale and preliminary data supporting the clinical development of BIO101. This treatment aims to preserve muscle and mobility in patients with obesity who are being treated with GLP-1 receptor agonists.
The ICFSR is known for its rigorous peer-review process, with all presented research being reviewed by the ICFSR Scientific Committee and published in the Journal of Frailty and Aging (JFA), a peer-reviewed publication specializing in aging and age-related diseases.
Biophytis SA (FP: ALBPS), a clinical-stage biotech company, has announced its strategic outlook for 2025, highlighting recent achievements and future plans. The company has strengthened its position through several key initiatives, including: launching the OBA clinical development program for obesity treatment, signing a strategic licensing agreement with Blanver, entering exclusive negotiations with a major Chinese pharmaceutical company, and establishing a co-development agreement with AskHelpU in ALS.
The company plans to accelerate the clinical development and commercialization of BIO101 (20-Hydroxyecdysone). Key initiatives include initiating Phase 2 OBA study for obesity treatment in collaboration with Blanver, targeting the obesity market projected to reach $100 billion by 2030. Additionally, Biophytis plans to launch Phase 3 of its SARA clinical program for sarcopenia, addressing a market of approximately 30 million patients in China with growing prevalence in Europe and the United States.
Biophytis SA (FP: ALBPS), a clinical-stage biotechnology company focused on age-related disease treatments, has announced its participation in the upcoming Biomed Forum organized by All Invest Securities. The event, scheduled for February 4, 2025 in Paris, is an annual healthcare sector conference that connects biotech and medtech companies with institutional investors. During the forum, Biophytis will have the opportunity to engage with French and European investors, provide company updates, and present its 2025 outlook.
Biophytis SA (BPTSY) has signed a co-development agreement with AskHelpU, China's largest ALS patient association, to evaluate the efficacy of BIO101, Biophytis' lead drug candidate, for Amyotrophic Lateral Sclerosis (ALS) treatment. The collaboration will leverage Biophytis' drug expertise and AskHelpU's disease knowledge, with research conducted at top Chinese universities.
BIO101, currently being developed for sarcopenia and obesity, could potentially offer a therapeutic solution for ALS, a severe neuromuscular disease affecting approximately 200,000 patients in China. ALS causes gradual muscle paralysis and affects speech and swallowing functions, with no current curative treatment available.
AskHelpU, founded in 2019 by former JD.com Vice President Cai Lei, has connected over 15,000 people across China and aims to help over one million people affected by neurodegenerative diseases. The organization has received significant funding, including a recent 100 million RMB donation announced in early 2024 for basic research.
Biophytis SA (OTC Pink: BPTSY) has entered exclusive negotiations with a leading Chinese pharmaceutical company to establish a licensing agreement for BIO101 (20-Hydroxyecdysone). The agreement aims to co-develop and commercialize BIO101 in China for treating viral respiratory infections, sarcopenia, and obesity.
The potential partner is part of a major Chinese group with expertise in innovative technologies and access to China's rapidly growing market. This development follows Biophytis' partnership strategy, building on their previous agreement with Blanver for the LATAM region. The Chinese market represents a significant opportunity, with 70 million obesity patients and 30 million sarcopenia patients. China is currently the second-largest pharmaceutical market globally, valued at $190 billion.
